Julian Upton

Biohaven CEO Vlad Coric talks to Pharm Exec about NURTEC ODT’s swift and seismic impact on the migraine market.

Closing the gaps in complex therapy data remains a hurdle, but “getting clever” with AI can offer a path forward.

How Gilead readied remdesivir for the COVID challenge.

How the UK is making progress in this hi-tech field.

Looking Back at 1997–1999.

Amgen is collaborating on two digital health initiatives aimed at improving heart failure care and rehabilitation.